Omeros: Novo Nordisk's Licensing Deal Sends Shares Soaring, Makes Bull Case (OMER)

Group 1 - Omeros Corporation's shares increased by over 150%, reaching $10.40 per share, marking their highest value since January [1] - The investing group Haggerston BioHealth provides insights into biotech, pharma, and healthcare sectors, including catalysts, buy/sell ratings, and financial forecasts [2] Group 2 - The group is designed for both novice and experienced biotech investors, offering detailed reports on over 1,000 companies [2]